explore -WSS

explore

author：focus 2025-09-07 06:44:35 - browse：92565

Miniature people figurines standing in a group looking down. -- health tech coverage from STAT — Adobe

In less than two years, digital health’s high-flying class of public debuts have landed with a resounding thud.

Accelerated by the pandemic’s forced adoption of telehealth and other digital health solutions, 2021 saw more than 30 health technology startups go public, raising hundreds of millions and in some cases billions of dollars. Today, three members of the class of 2021 have gone bankrupt. Twelve companies have lost more than 90% of their initial value, including Bright Health Group, Cue Health, and Better Therapeutics. And dangerously low reserves have inspired desperate moves to slash costs, drum up liquidity, and find buyers.

Most recently, the bankruptcy of digital primary care company Babylon Health has drawn attention to the plight of newly-public health tech companies, and how the froth of dealmaking at the height of the pandemic led to overblown valuations. Before its debut in June 2021, Babylon was valued at $4.2 billion; after filing for bankruptcy in August, its U.K. telemedicine business was sold for just over $600,000.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Heart attack and stroke risk calculators need revising
Next article： Leqembi, other new Alzheimer’s drugs require better biomarkers

WSS

Racing yachts have close encounter with pod of orcas near Strait of Gibraltar

A preacher's new calling: Diversifying neuroscience research

Why 40% Americans with Parkinson’s don’t see a neurologist

Arena BioWorks launches in Cambridge to speed drug discovery

Life science postdocs should get big pay hike, NIH panel says

Oak trusses raised to roof of fire

hotspot

explore

entertainment

State Dept. review finds Biden bears some blame for Afghanistan failures

Biden launches a new push to limit health care costs

Virginia high school admissions case could be legal follow

It's time to get medical device identifiers over the finish line

Medicare proposal to cover medical devices draws a mixed reaction

Lecanemab for Alzheimer's is coming. Is the health system ready?

DIEP, the 'gold standard' of breast reconstruction, is under threat

At JPM 2024, hospital systems pitch financial strength to investors

Wildfire smoke exposes gaps in outdoor worker protections

At JPM 2024, hospital systems pitch financial strength to investors

entertainment

Charles Manson follower Leslie Van Houten released from prison after 53 years

Leqembi, other new Alzheimer’s drugs require better biomarkers

Medicare Advantage overpayments discussion gets experts fired up

HCA discloses massive data breach affecting 11 million patients

How the political right came to back psychedelics to treat trauma

Readout Newsletter: Cytokinetics and Novartis' starcrossed tale

leisure time

knowledge

focus

focus